Document Type
Article
Publication Date
4-26-2018
Publication Title
Journal of Medicinal Chemistry
ISSN
0022-2623
Volume
61
Issue/No.
8
First Page
3738
Last Page
3744
Abstract
β-Defensin 3 (BD3) was identified as a ligand for the melanocortin receptors (MCRs) in 2007, although the pharmacology activity of BD3 has not been clearly elucidated. Herein, it is demonstrated that human BD3 and mouse BD3 are full micromolar agonists at the MCRs. Furthermore, mouse β-defensin 1 (BD1) and human BD1 are also MCR micromolar agonists. This work identifies BD1 as an endogenous MCR ligand and clarifies the controversial role of BD3 as a micromolar agonist.
NSUWorks Citation
Ericson, Mark D.; Singh, Anamika; Tala, Srinivasa R.; Haslach, Erica M.; Dirain, Marvin L.; Schaub, Jay W.; Flores, Viktor; Eick, Natalie; Lensing, Cody J.; Freeman, Katie T.; Smeester, Branden A.; Adank, Danielle N.; Wilber, Stacey L.; Speth, Robert; and Haskell-Luevano, Carrie, "Human β-Defensin 1 and β-Defensin 3 (Mouse Ortholog mBD14) Function as Full Endogenous Agonists at Select Melanocortin Receptors" (2018). HPD Articles. 93.
https://nsuworks.nova.edu/hpd_facarticles/93
ORCID ID
0000-0002-6434-2151
DOI
10.1021/acs.jmedchem.8b00251
Copyright
Copyright © 2018 American Chemical Society